Lyme Disease Vaccine Candidate Just Misses Its Mark in Late-Stage Trial

(MedPage Today) -- WASHINGTON -- An investigational Lyme disease vaccine covering six serotypes across four Borrelia species had a vaccine efficacy (VE) rate of over 70%, but it just missed a preset noninferiority threshold, a placebo-controlled...